El webinar Vacunas e Inmunización, evento desarrollado en conjunto con Geneva Network

El webinar Vacunas e Inmunización, evento desarrollado en conjunto con Geneva Network, con las palabras de bienvenida de nuestro director ejecutivo.

Contamos con la participación de la Dra. María Luisa Ávila, exministra de Salud Pública de Costa Rica; Dr. Roberto Tapia-Conyer, profesor de Posgrado de la UNAM México; y, el Dr. Luis Sarrazín, exministro de Salud Pública del Ecuador.

La Dra. Maria Luisa Ávila presenta un informe sobre la gestión de la salud pública en Costa Rica y el proceso de vacunación a la población.

Interviene el Dr. Roberto Tapia-Conyer, con su charla “La pandemia Covid-19: oportunidades para la revisión de las políticas públicas en vacunación”.

El Dr. Roberto Tapia-Conyer, profesor de la Universidad Autónoma de México, señala que en ese país existe una ventana de oportunidad para mejorar las coberturas actuales de vacunación contra la influenza.

El Dr. Luis Sarrazín, exministro de Salud Pública del Ecuador realiza un análisis de la situación actual del Covid-19 en Latinoamérica y el país.

La importancia de continuar los programas ordinarios de inmunización durante la pandemia de Covid-19: Perspectivas latinoamericanas

La pandemia de Covid-19 ha resaltado la importancia de la atención médica ordinaria que muchas veces damos por sentado. Los gobiernos alrededor del mundo han instituido mecanismos de control del virus que buscan retardar la transmisión de los contagios, garantizando así que los hospitales y las unidades de cuidado intensivo no colapsen. Una consecuencia lamentable de estas intervenciones ha sido el impacto en la provisión de atención médica ordinaria. En todo el mundo no se están diagnosticando otras enfermedades, se están atrasando tratamientos –o no se están brindando del todo– y se han cancelado o pospuesto cirugías.

En Ecuador y otras partes de América Latina, los programas ordinarios de vacunación han sido una víctima importante de la pandemia de Covid debido a la renuencia de la gente a salir de la casa, interrupciones en el transporte, dificultades económicas, restricciones al movimiento, o el temor a verse expuesto personas contagiadas.

Con el fin de explorar la importancia de la inmunización aun cuando se desarrolla una pandemia de grandes proporciones, la Geneva Network convocó a un panel de expertos latinoamericanos para un webinar patrocinado por nuestros amigos de la Federación Nacional de Cámaras de Comercio de Ecuador.

Repasando sus propias experiencias y enseñanzas, nuestros destacados oradores resaltaron la importancia social y económica de la vacunación y enfatizaron la necesidad de que la gente y las autoridades de salud apoyen esta poderosa y rentable intervención sanitaria.

Para leer una revisión completa del seminario web, descargue la revisión aquí.

Webinar: The importance of continuing regular immunization during the Covid-19 pandemic: Latin American perspectives

The Covid-19 pandemic has highlighted the importance of the regular healthcare provision we take for granted. Governments all over the world have instituted virus control measures that aim to slow the spread of infection, thereby ensuring hospitals and intensive care units do not become overwhelmed and collapse. One unfortunate by-product of these interventions has been the impact on regular healthcare provision. All over the world, non-Covid diseases are not being diagnosed, regular treatments are being delayed or skipped altogether, and surgeries have been cancelled and postponed.

In Ecuador and elsewhere in Latin America, regular immunization programmes have been significant casualty of the Covid pandemic due to a reluctance to leave home, transport interruptions, economic hardships, restrictions on movement, or fear of being exposed to people with Covid-19.

To explore the importance of continued immunization even while a major global health pandemic is unfolding, Geneva Network convened a panel of Latin American experts for an online webinar hosted by our friends at the National Federation of Chambers of Commerce in Ecuador.

Citing their own experiences and learning, our eminent speakers laid out the social and economic importance of vaccination and stressed the need for people and health leaders to support this most cost-effective and powerful healthcare intervention.

To read a full review of the webinar download the review here.

Click here to see report from Twitter.

“Evergreening”, medical innovation and patents: separating fact from fiction

The extent to which follow-on pharmaceutical innovations should be protectable by patents is hotly debated amongst the public health and IP community in Geneva. But are fears that follow-on patents simply extend indefinitely, or “evergreening”, medicine patents justified?

Drawing on global experiences and real-world evidence, this working lunch examined what exactly is follow-on pharmaceutical innovation, how it impacts public health, and whether national patent laws should treat it differently to other forms of medical innovation.

The common theme amongst participants that “evergreening” is a problematic concept, and that follow-on innovations have produced real benefits for patients, and the ability to secure patents has been a critical incentive to underpin R&D in these areas.

Participants included representatives from the diplomatic community, multilateral organisations, academia and the private sector.

Prof Timo Minssen of the University of Copenhagen presented the findings of his recent joint paper Patentability Standards for Follow-On Pharmaceutical Innovation. He cited numerous examples from jurisdictions around the world in which patent offices and courts have applied the well-recognized requirements of patentability, including patent eligibility, novelty, inventive step and industrial application, to follow-on pharmaceutical inventions, and in so doing have advanced innovation in public health and ultimately the lives of patients.

He also put into perspective the concept of “evergreening”, pointing out that – unless there is a clear misuse of the regulatory system – a patent on an improved formulation, for example, is limited to that improvement and does not extend patent protection for the original formulation – and nor does it impede generic entry for the original version.

Of course, this assumes a reasonably well-functioning pharmaceutical market and competition. If that market breaks down in a manner that forces patients to pay higher prices for a patented new version of a drug that provides little real improvement over the original formulation, then it is the deficiency in the market or the regulatory system which should be addressed, rather than the patent system itself.

Finally, he emphasised the role of competition law in countering abuses of the patent system, and the mitigating effects of correctly and coherently applied patentability criteria. If the traditional patentability criteria are applied, there are no need for new ones.

Prof Prabuddha Ganguli of the Rajiv Gandhi School of Intellectual Property Law gave his perspective as an IP practitioner who has drafted and defended dozens of patents within the Indian patent regime. He explained the importance of follow-on innovation within medicine and discussed the details of section 3d of the Indian Patent Act and how that has forced innovators in India to change and adapt their approach to R&D and patent drafting. The ability to patent follow-on innovations has been particularly critical to help generic companies boost their innovative capacity and take their first steps into de novo drug R&D – critical for the long-term future of the Indian pharmaceutical industry.

Peter Thomsen of Novartis outlined the importance of patents to support investment in R&D into follow-on innovations, giving several examples of important follow-on medicines and formulations that have depended on patent protection. In his view, it would be a mistake to discriminate against these kinds of technologies within the patent system given their importance to innovation and advances in medical technology.

IP as a Driver of Competitiveness and Growth: Policy Challenges and Opportunities

World IP Forum, Taiwan

MODERATOR:

  • Philip Stevens, Executive Director, Geneva Network (UK)

PANELISTS:

Click here for more information: https://www.worldipforum.com/index.php

WTO Public Forum panel on digital trade and health

Digital services hold enormous potential for improving healthcare delivery around the world, according to a panel convened by Geneva Network and the Information Technology and Innovation Foundation at this year’s WTO Public Forum. However, governance and trade issues need to be resolved to ensure the best management and cross-border flow of data.

Read a full account of the discussion here.

Panellists included:

Intellectual property ASEAN

24th September 2019 – Manila launch of think tank coalition report

Intellectual property ASEAN

A reform agenda for ASEAN countries

The event will take place at the Holiday Inn Makati, in the Philippines, and will see the launch of a think tank coalition report: “The importance of Intellectual Property Rights for progress: a reform agenda for ASEAN countries”.

Keynote Speaker, Hon. Ramon M. Lopez, Secretary, Department of Trade and Industry, followed by presentation of the report by Philip Stevens, Executive Director, Geneva Network.

View the programme here.